To our knowledge, CCR2 inhibition in combination with ICB immune therapies has not been previously tested in PDA, especially using autochthonous disease that arises in the KPC model, and we focused on preclinical drug combinations that could be clinically viable (i.e., that include a standard-of-care chemotherapy). This evidence concerns the gene CCR2 and Patent ductus arteriosus.